We are live on ! Find out more
BSPM

Biostar Pharmaceuticals, Inc.
BSPM

Delisted

BSPM was delisted on the 18th of September, 2018.

Back to rankings

10 hedge funds and large institutions have $1.39M invested in Biostar Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

60% more capital invested

Capital invested by funds: $870K → $1.39M (+$518K)

9% less funds holding

Funds holding: 11 → 10 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
10
Holders Change
-1
Holders Change %
-9.09%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$500K
2
SIM
Spark Investment Management
New York
+$39.4K
3
N
Natixis
France
+$33.5K
4
AL
Airain Ltd
Guernsey
+$27.2K
5
TRCT
Tower Research Capital (TRC)
New York
+$21K

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$26K
2
Citigroup
Citigroup
New York
-$3K

BSPM Hedge Fund Activity: Q1 2014 in Review

10 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q1 2014, worth a combined $1.39M — up 60% from $870K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BSPM and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $500K. The largest seller was Virtu KCG Holdings, cutting an estimated $26K.

  • 10 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q1 2014, down from 11 in Q4 2013.
  • Funds reported $1.39M of Biostar Pharmaceuticals, Inc. stock for Q1 2014, up 60% quarter-over-quarter.
  • 1 fund opened new Biostar Pharmaceuticals, Inc. positions in Q1 2014 and 2 closed out, a net change of -1 holder.
  • The largest Biostar Pharmaceuticals, Inc. buyer in Q1 2014 was Renaissance Technologies, an estimated $500K added.
  • The largest Biostar Pharmaceuticals, Inc. seller in Q1 2014 was Virtu KCG Holdings, an estimated $26K sold.

Based on aggregated 13F filings for Q1 2014.